Volume 49, Issue 3 pp. 351-357
Original Article

Hepatitis C treatment for difficult to access populations: can telementoring (as distinct from telemedicine) help?

Waled Mohsen

Waled Mohsen

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

These authors contributed equally to this study.Search for more papers by this author
Patrick Chan

Patrick Chan

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia

These authors contributed equally to this study.Search for more papers by this author
Michelle Whelan

Michelle Whelan

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

Search for more papers by this author
Ann Glass

Ann Glass

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

Search for more papers by this author
Marlize Mouton

Marlize Mouton

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

Search for more papers by this author
Ernest Young

Ernest Young

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

Search for more papers by this author
Quyen Tran

Quyen Tran

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

Search for more papers by this author
Sanjeev Arora

Sanjeev Arora

Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA

Search for more papers by this author
Scott Davison

Scott Davison

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia

Search for more papers by this author
Tenzin Lama

Tenzin Lama

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia

Search for more papers by this author
Cherry Cobrador

Cherry Cobrador

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

Search for more papers by this author
Miriam Levy

Corresponding Author

Miriam Levy

Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia

South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia

Correspondence

Miriam Levy, South Western Sydney Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.

Email: [email protected]

Search for more papers by this author
First published: 08 August 2018
Citations: 28
Funding: None.
Conflict of interest: None.

Abstract

Background

Although hepatitis C virus (HCV) infection is curable, treatment of difficult to access populations (DTAP) presents unique challenges. Project ECHO (PE) (Extension for Community Healthcare Outcomes) is a telementoring programme adopted to support clinicians treating DTAP.

Aims

To determine if the PE model supports primary care clinicians treating HCV and to compare cohort of PE patients with those in a tertiary liver clinic (TLC).

Methods

Weekly PE group video conferences were conducted. Clinical information, laboratory indices, psychosocial elements and treatment outcomes, including sustained virological response (SVR) data were recorded in the first 100 consecutive cases and retrospectively compared to 100 consecutive patients seen at a TLC from July 2016 to April 2017.

Results

Some patient characteristics were similar between PE and TLC: gender (72% vs 75% male; P = 0.23), median age (45 vs 50; P = 0.344) and the proportion of treatment naïve patients (95.0% vs 90.9%). Treatment for HCV was commenced in 78% of the PE patients and 81% of the TLC patients; 67/68 of the TLC patients and 60/61 PE patients with virological follow up who completed treatment and attended follow up have confirmed SVR. PE patients are more likely to have ongoing substance use (44% vs 17% P < 0.001), be active intravenous drug users (32% vs 17%; P < 0.001) and polysubstance abusers (26% vs 7%; P < 0.001) and were more likely to be taking opioid substitution therapy (74% vs 20%; P < 0.001). Indigenous patients were three times more greatly represented in PE (15% vs 5%; P = 0.018).

Conclusion

PE is an effective model to support primary healthcare providers treating HCV in DTAP with similar rates of treatment uptake and SVR compared to patients in TLC.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.